• About us
• Contact

Advertisement

Organisation › Details

Fulcrum Therapeutics Inc. (Nasdaq: FULC)

Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum's therapies are based on 3 modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass. *

 

	Start	2016-07-01 established
	Industry	BIOTECH
	Industry 2	losmapimod
	Person	Gould, Robert J. (Fulcrum Therapeutics 201607– CEO before Epizyme + Broad Institute + Merck Research Labs)
	Region	Cambridge, MA
	Country	United States (USA)
	Street	26 Landsdowne Street
	City	02139 Cambridge, MA
	Tel	+1-617-651-8851
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2023-09-21

Advertisement

More documents for Fulcrum Therapeutics Inc. (Nasdaq: FULC)

• [1] Atavistik Bio Inc.. (7/17/23). "Press Release: Atavistik Bio Appoints Bryan Stuart as Chief Executive Officer". Cambridge, MA....
• [2] Fulcrum Therapeutics, Inc.. (9/4/19). "Press Release: Fulcrum Therapeutics Appoints Pamela Strode, Seasoned Industry Executive, to Lead Regulatory Affairs Team". Cambridge, MA....
• [3] Fulcrum Therapeutics, Inc.. (9/3/19). "Press Release: Fulcrum Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference". Cambridge, MA....
• [4] Fulcrum Therapeutics, Inc.. (7/17/19). "Press Release: Fulcrum Therapeutics Announces Pricing of Initial Public Offering". Cambridge, MA....
• [5] Fulcrum Therapeutics, Inc.. (4/23/19). "Press Release: Fulcrum Therapeutics Acquires Global Rights to Losmapimod, a Potential Disease-Modifying Therapy for Facioscapulohumeral Muscular Dystrophy". Cambridge, MA....
• [6] Fulcrum Therapeutics, Inc.. (9/5/18). "Press Release: Fulcrum Therapeutics Announces $80 Million Series B Financing". Cambridge, MA....
• [7] Fulcrum Therapeutics, Inc.. (5/10/17). "Press Release: Fulcrum Therapeutics Announces Additional Series A Financing from GV". Cambridge, MA....
• [8] Axxam S.p.A.. (2/1/17). "Press Release: Axxam and Fulcrum Therapeutics Initiate a Partnership for the Provision of Drug Discovery Services for Genetic Diseases"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.